Search results
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth...
Digital Journal· 6 days agoCatherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management of oral mucositis ...
Comprehensive Review Highlights Potential Benefits of Leukine® in Management of Gastrointestinal...
The Pendulum· 6 days agoLeukine is not FDA approved for treatment of irAEs or melanoma.
Maalox Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD
WebMD· 6 days agoNausea, constipation, diarrhea, or headache may occur. The magnesium in this product can cause diarrhea. Using an antacid that contains only aluminum along with this product can help control ...
Icosapent Ethyl Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD
WebMD· 3 days agoRemember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have ...
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional...
WLNS Lansing· 11 hours agoXTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the European Union ( ...
Cefpodoxime Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD
WebMD· 7 days agoRemember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have ...
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS)...
The Joplin Globe· 2 days agoSAN FRANCISCO, CA / ACCESSWIRE / April 22, 2024 / Jaguar Health, Inc. ( NASDAQ:JAGX ) ("Jaguar") today announced that Jaguar family company Napo Pharmaceuticals ("Napo") is exhibiting at the ...
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Morningstar· 2 days agoFood and Drug Administration (FDA) for the treatment of patients with relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). FDA granted BTD ...
Glytec Announces Support for Landmark New CMS Measures to Improve Diabetes Reporting
WFRV 5 Green Bay· 6 days agoGlytec, whose industry leading SaaS platform empowers collaborative diabetes management and insulin dosing from the hospital to the home, announces a major step forward in its advocacy and partnership ...
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the...
Morningstar· 2 days agoKrystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the first patient was dosed in its Phase 1 clinical trial (KYANITE-1) evaluating ...